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Objectives To examine the association between β-blocker prescription and knee or hip total joint replacement
(TJR) in a UK primary-care population with incident knee or hip osteoarthritis (OA).
Methods Cohort study using data from the Clinical Practice Research Datalink. Participants aged ≥40 years
with incident knee or hip OA, exposed to β-blockers after OA diagnosis (new-user design), were matched to
one control for age, sex, OA location and propensity score (PS) for β-blocker prescription. Cox-proportional
hazard ratios (HRs) and 95% con dence intervals (CI) were calculated. The analyses were adjusted for
factors that in uence health-seeking behaviour, progression of OA, and strati ed according to β-blocker
classi cation. Data analysis was conducted using Stata.
Results Data for 6,970 PS-matched β-blocker exposed and unexposed participants were included. Any β-
blocker prescription was not associated with knee or hip TJR (aHR 1.11; 95% CI 0.98 – 1.25). However,
prescription of lipophilic non-selective β-blockers having membrane stabilising effects associated with
reduced risk of knee or hip TJR (aHR 0.69; 95% CI 0.52 – 0.93). Of these, there was a protective effect for
propranolol (aHR 0.71; 95% CI 0.53 – 0.95), the commonest prescribed drug in this class. The number needed
to treat (95% CI) with propranolol for two years in order to prevent one TJR was 32 (23-52).
Conclusion Propranolol, a non-selective β-blocker, reduces the risk of knee and hip TJR. This is consistent with
its analgesic effects in other conditions and a randomised controlled trial is required to further evaluate its
analgesic potential and safety in OA.
Key Message
What is already known about this subject? 
There is paucity of safe and effective analgesic drugs for OA.
β-adrenoreceptor blockers have demonstrated anti-nociceptive effects in several painful conditions.
What does this study add? 
Propranolol, a non-selective β-blocker, reduces the risk of knee and hip TJR in people with OA.
How might this impact on clinical practice or future developments?
Propranolol may be used as an analgesic for OA-pain if these  ndings are con rmed in a clinical trial.
Introduction
Osteoarthritis (OA) is the commonest form of arthritis and affects approximately 1 in 4 adults older than 45
years in age(1). There is a paucity of effective structure-modifying drug for OA, and, analgesics only have a
modest effect size (ES) and may cause troublesome and potentially serious side-effects(2, 3). Consequently,
many people undergo total joint replacement (TJR), most commonly at the knee or the hip. An estimated 1.9
million knee or hip TJRs are projected to be performed each year in the USA alone by the year 2030(4).
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Our recent research demonstrated that β-adrenoreceptor blocking drugs (β-blockers) atenolol and propranolol
have anti-nociceptive effects on knee and/or hip pain, with the largest ES for propranolol(5). Prior to this, we
reported lower opioid consumption and less severe joint pain in people with large-joint lower limb OA
prescribed β-blockers(6), and β-blocker prescription associated with lower opioid use at day 30 in another
study on patients undergoing knee TJR(7). However, this was not con rmed in a study using Osteoarthritis
Initiative (OAI) data(8). Whether β-blockers reduce incidence of TJR in people with OA is not known. In
intervention studies, propranolol, a β-blocker drug, has analgesic bene t on musculoskeletal pain due to
 bromyalgia and temporomandibular joint dysfunction and reduces post-operative analgesic requirement(24-
26). It may be particularly suitable as an analgesic for OA with comorbid anxiety(28), neuropathic pain non-
responsive to NSAIDs and driven by β2 adrenoreceptor stimulation(18), and those with low catechol-O-
methyltransferase (COMT) gene activity(29). The latter is of particular mechanistic relevance as >70%
Caucasians have COMT (158Met) polymorphisms that confers low COMT gene activity(30).
Thus, the objective of this study was to examine whether β-blocker prescription associates with a lower risk of
lower limb arthroplasty in a primary-care population with knee or hip OA.
Methods
Study Design: Cohort study.
Data source: Data from CPRD were used. Incepted in the year 1987, CPRD is a longitudinal anonymised
electronic database containing health records of >10 million people in the UK(9). CPRD participants are
representative of the UK population in terms of age, sex, and ethnicity(9).
Ethical approval: ISAC of the Medicines and Healthcare products Regulatory Authority (ISAC Reference:
18_227R).
Study population: Age ≥40 years, diagnosed with knee or hip OA between 1st January 1990 and 31st
December 2013, at-least 2-year disease and exposure free prior registration in the CPRD before OA diagnosis,
and contributing acceptable research quality data in up-to-standard GP practices (Appendix 1).
Exposure: New continuous β-blocker prescription, de ned as ≥2 prescriptions of β-blockers within a 60-day
period after the  rst OA diagnosis (new user design).
Unexposed: Participants without a prescription of β-blocker, or with a single β-blocker prescription after OA
diagnosis date, matched to exposed participants for age at OA diagnosis (5-year age band), sex, OA location
(knee or hip) and propensity score (PS) for β-blocker prescription (Appendix 1).
Start of follow-up (index date): Date of  rst β-blocker prescription for the exposed. The duration between OA
diagnosis date and  rst β-blocker prescription date in the exposed was added to the OA diagnosis date of the
matched unexposed to obtain their start of follow-up date. Thus, the exposed and matched unexposed
participants had the same duration of OA prior to start of follow-up. This minimised any potential bias due to
unequal disease duration prior to start of follow-up in exposed and unexposed participants as the risk of joint
replacement increases with duration of OA(10). If this approach was not taken, exposed participants would
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have had longer follow-up with OA prior to cohort entry (time taken to develop a comorbidity for which beta-
blockers may be prescribed) and consequently be at higher risk of outcome. 
Outcomes: [1] Knee or hip TJR (primary outcome), [2] knee TJR, and [3] hip TJR.
Exclusion criteria:
[1] Consultation for the below prior to start of follow-up:
Conditions causing chronic pain: autoimmune in ammatory rheumatic diseases (rheumatoid arthritis,
psoriatic arthritis, ankylosing spondylitis, lupus, polymyalgia rheumatica); gout; radiculopathy;
neuropathy; and  bromyalgia.
Contra-indications for β-blockers: chronic obstructive pulmonary disease or asthma; peripheral vascular
disease; heart block, aortic stenosis, and hypertrophic obstructive cardiomyopathy.
[2] Knee or hip TJR prior to or within 90 days of start of follow-up. Knee or hip TJR within 90 days after start of
follow-up were excluded as we do not expect β-blockers to in uence the rate of TJR immediately, and they
may have been commenced during a pre-anaesthetic check-up.
End follow-up: Exposed participants were followed up from the index date. Participant follow-up ended at the
earliest of date of  rst outcome, death date, transfer out date, date of last data collection, or study end
(31/12/2018).
Ascertainment of exposure, outcomes and covariates: Read codes and product codes were used to ascertain
these factors (Appendix 2).
Statistical Analyses: As participants prescribed β-adrenoreceptor blocking drugs are likely to have
comorbidities, be older and have a high body mass index (BMI), a PS for β-blocker prescription was
calculated using a cumulative logit regression model. Greedy nearest neighbour 1:1 matching, without
replacement specifying a maximum calliper width of 0.001, was undertaken to match the exposed to
unexposed participants. Missing values for BMI and smoking status were categorised as missing data for the
purpose of PS matching as people with healthy lifestyle and normal BMI are more likely to have missing data
in consultation-based databases such as CPRD where lifestyle and demographic factors are collected
opportunistically(11). Mean, standard deviation (SD), n (%), and standardised mean difference (SMD) were
used to examine the covariate balance between matched exposed and unexposed participants. Any variables
that were in imbalance after PS matching were included in the model if the SMD was >0.10 as
recommended(12).
Hazard ratios (HRs) and 95% con dence interval (CI) were calculated for each incident outcome ( rst Read
code for the event) using a Cox proportional hazards model. Covariates that are likely to in uence outcomes,
e.g. progression of OA, or re ect health-seeking behaviour were included in the Cox model for additional
confounder adjustment. These were:
number of GP consultations for knee or hip injury, non-osteoporotic fractures (de ned as fractures in any
bone except the femur, distal radius, and vertebrae after the age of 18 years but before the age of 50
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years in women and 60 years in men) prior to start of follow-up,
number of analgesic prescriptions between the  rst consultation for knee/hip OA and start of follow-up,
number of GP consultations, hospital out-patient referrals, hospital admissions in the 12-month period
preceding start of follow-up,
bisphosphonate or glucosamine/chondroitin sulphate prescription in the 12-month period prior to start of
follow-up,
new diagnosis of interphalangeal or thumb base OA, neck or back pain or spinal degenerative diseases
after start of follow-up.
These analyses were strati ed according to class of β-blocker drug used namely, β1 selective, intrinsic
sympathomimetic activity, membrane stabilising effect, and lipophilic properties (low versus high). Number
needed to treat (NNT) and 95% CI for a 2-year treatment duration were computed using the aHR and survival
probability in control group as described previously(13).
Additionally, we performed multiple imputation to handle missing BMI values and smoking status using
chained equations as a sensitivity analysis. Demographic factors, relevant diagnoses and prescriptions
(Appendix 3), covariates that are likely to in uence outcomes or re ect health-seeking behaviour listed above,
primary outcome variable, and Nelson-Aalen estimator of baseline cumulative hazard were included in the
imputation model as recommended(14). Ten imputed datasets were created to account for random
variability(15). PS calculation, matching and Cox regression analyses were undertaken in each imputed
dataset. However, we did not  nd substantial difference between the results with missing values as a dummy
category and the imputed values (see Tables S1, S2, and S3 in the supplementary material). Thus, results are
only reported with the missing category approach. Data management and analysis were performed in Stata
MP v15.
Results
Data for 13,620 participants exposed to β-blockers and up to  ve age, sex and OA location matched
unexposed participants (n = 48,636) were ascertained during the study period. Of these, data for 6,970 PS-
matched β-blocker exposed (n = 3,485), and unexposed (n = 3,485) participants contributing 42,066 person-
years of follow-up were analysed (Appendix 2). The majority of participants that had knee OA (81.12%), more
than half our participants were women (57.89%) and the mean (SD) age at OA diagnosis was 65 (11) years.
There was covariate balance between exposed and unexposed after PS-matching on all covariates except for
hypertension (SMD = 0.115) for which there was minor imbalance (Table 1). Hypertension was included in the
model as a covariate to account for the imbalance. After PS matching, unexposed participants had a similar
number of consultations with their GP in the preceding 12-months as the exposed, with median (Inter Quartile
Range) 11 (6 to 18) and 11 (7 to 18) GP visits, respectively.
Overall β-blocker prescription was not associated with hip or knee TJR (aHR 1.11; 95% CI 0.98–1.25), knee
TJR (aHR 1.14; 95% CI 0.98 − 1.34) and hip TJR (aHR 1.23; 95% CI 0.96–1.57) (Table 2). Similar results were
observed on the assessment of beta-blocker classes except for β-blocker with MSE which showed a reduction
in the risk of knee or hip TJR (aHR 0.69; 95 % CI 0.52–0.93). The NNT (95%CI) to prevent joint replacement at
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2 years follow-up was 32 (23–52). When data were strati ed according to individual drugs, there was a
protective effect for propranolol but an increase in the risk of knee or hip TJR for atenolol (Table 3; Fig. 1).
Discussion
This primary-care based PS-matched study reports that propranolol, a non-selective lipophilic β-blocker with a
membrane stabilising effect and without intrinsic sympathomimetic activity, reduced risk of TJR. This
accords with our previous study results where propranolol associated with reduced primary-care consultation
for knee OA and knee pain, with reductions of 22% and 20%, respectively.
The analgesic effects of propranolol may be mediated by directly blocking the β2 adrenoreceptors on the
peripheral nociceptors, dorsal root ganglia, and super cial dorsal horn (16–18), or by indirect effects such as
a reduction in the negative affective component of pain (19), regulation of the  ring of periaqueductal grey
neurons via gamma-Amino butyric acid (GABA)-mediated action, and interfering with the chronic sensitization
processes in the rostral ventromedial medulla and locus coeruleus (20, 21). Additional mechanisms may
include a potentiation of the analgesic effect of sub-therapeutic doses of opioids via dopaminergic and GABA
receptor mediated pathways (22). Propranolol also induces in ltrative cutaneous analgesia by blocking the
voltage sensitive Sodium (Na+) and Calcium (Ca2+) ion channels, reducing Na + and Calcium Ca2 + in uxes,
and decreasing intracellular cyclic adenosine monophosphate via reduction of adenyl cyclase activity (23) .
Our  ndings are broadly consistent with the results of some observational studies reporting less severe pain
and lower analgesic requirements in people with OA prescribed β-blockers (6, 7). However, they do not accord
with those of a study using data from the OAI which reported no difference in pain severity between people
prescribed and not prescribed β-blockers. This may be due to a lack of power, with a modest sample size of
1,168 and only 15% of participants being exposed to β-blockers (27).
In the present study, atenolol prescription associated with an increased risk of TJR and this was an
unexpected  nding given the results of our previous study in which atenolol reduced the risk of incident knee
pain. This discordance may be due to the fact that β1-adrenoreceptor blockade reduces bone resorption and
increases bone mineral density (31), and increased bone mineral density associates with an increased risk of
TJR (32). Increased bone mineral density is also causally associated with end-stage OA according to a
mendelian randomisation study using data from the UK biobank (33). Unlike β1-adrenoreceptor blockade, β2-
adrenoreceptor blockade with propranolol does not affect bone resorption or increase bone mineral density
(31).
The  nding of this study needs to be con rmed in a randomised controlled trial and the safety of propranolol
in this population needs to be demonstrated before propranolol may be adopted as an analgesic for OA. The
NNT estimated from the present study is high. Strengths of the present study include a large sample size,
balanced PS matched exposed and un-exposed groups, and adjustment for other covariates that re ect
health-seeking behaviour or are recognised as potential risk factors for TJR in OA. GPs are the  rst port of call
for people with chronic conditions in the UK, and it is extremely unlikely that someone with OA will be seen in
a secondary care hospital service, including private settings, without consulting their GP  rst. Participants
with less than two-year registration in the GP practice before the OA diagnosis date were excluded to reduce
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the risk of prevalent cases being included as incident OA. We excluded participants with chronic painful
conditions and contra-indications to β-blockers to minimise confounding by indication that may not be
addressed by PS matching. We used a validated de nition of primary care diagnosis of knee or hip OA to
de ne the onset of follow-up period (34, 35) and did not de ne our population just on consultation for knee or
hip joint pain. Similarly, we used a GP entry of joint replacement surgery to de ne our outcomes. This has
been validated against Hospital Episode Statistics and UK joint registry data and shown to have excellent
validity (36, 37). Only 60% of CPRD practices are linked to HES and restricting the dataset to such practices
would result in loss of sample size.
However, there are several caveats to this study. Firstly, we used primary care diagnosis of knee or hip OA.
This is likely to be later than the onset of symptoms. However, there is no reason to suspect that this delay
will differ between exposed and unexposed individuals. The exposure status was based on prescription and
not on actual drug taking. However, this will only bias the results towards a null effect. We dichotomised the
exposure as present or absent. Further dose response analysis, examining the association between
cumulative doses is warranted. We did not use individuals initiating another drug (i.e. active comparator) as
controls because there is a hierarchy in the use of different drugs for the treatment of cardiovascular diseases
in the UK driven by NICE guidelines. For instance, the NICE guidelines recommend beta-blockers to treat
resistant hypertension that has failed to respond to most other anti-hypertensive agents including ACE
inhibitors, angiotensin-II receptor blockers, diuretics and calcium channel blockers. On the contrary, they
recommend beta-blockers as  rst-line drugs for treatment of atrial  brillation, angina and heart failure. Thus,
an active comparator study design, even when strati ed according to the cardiovascular disease, would
introduce greater bias. Primary-care prescriptions in the UK are typically issued for 4 weeks at a time. In this
study, exposed participants were required to receive 2 prescriptions in a 60-day period in order to enrich the
sample with participants likely to continue with β-blocker treatment. This potentially introduces immortal time
bias as follow-up started with  rst prescription date. However, both exposed and unexposed participants were
required to have at-least 90 days follow-up without TJR, immortal time bias does not affect the validity of our
 ndings. Finally, despite our best efforts residual confounding by indication may remain.
Conclusion
In summary, we report that the non-selective β-blocker propranolol reduces the risk of knee or hip TJR. A
randomised controlled trial is required to further evaluate the analgesic potential of propranolol in OA.
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5.94 (2.86) -0.026 5.87
(2.89)
5.81 (2.87) 0.020





0.83 (3.43) 0.101 1.12
(3.91)
1.28 (3.82) -0.042
Duration of hypertension* 4.07
(6.97)
3.39 (6.51) 0.101 4.27
(7.34)
4.71 (6.26) -0.065





































Smoking missing data 256
(5.52)












































SMD: Standardised mean difference * Duration in years of cardiovascular comorbidities prior to index
date.
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251 (2.75) 0.320 240
(6.89)
192 (5.51) 0.057
Congestive cardiac failure 285
(6.14)










496 (5.44) 0.048 232
(6.66)
254 (7.29) -0.025
Chronic kidney disease 336
(7.24)


























133 (1.46) 0.097 92
(2.64)
96 (2.75) -0.007































































SMD: Standardised mean difference * Duration in years of cardiovascular comorbidities prior to index
date.
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The association between β-adrenoreceptor blocking drug prescription and knee or hip joint replacement
Outcomes Exposed Events Person-
time
(years)










No 459 17,637 26.02 (23.75–28.52) 1.00 1.00








No 278 14,730 18.87 (16.78–21.23) 1.00 1.00








No 119 2,782 42.77 (35.74–51.19) 1.00 1.00






1PS matched. 2 As in model 1, and, additionally adjusted for number of GP consultations, hospital out-
patient referrals, hospital admissions and number of bisphosphonate, glucosamine/chondroitin sulphate
prescription in the 12 month period preceding index date; total number of GP consultations for knee or hip
injury, non-osteoporotic fractures, hand osteoarthritis, neck or back pain or spinal degenerative diseases,
hypertension, duration of OA prior to index date; number of analgesic prescription between the  rst




The association between β-adrenoreceptor blocking drug prescription and knee or hip replacement: strati ed















Unexposed1 459 17,637 26.02 (23.75–
28.52)
1.00 1.00
β-blocker class ≠          


































β-blocker drug name          


















1Comparison group is unexposed to β-blockers; 2Propensity score matched; 3As in model 1, and,
additionally adjusted for number of GP consultations, hospital out-patient referrals, hospital admissions
and number of bisphosphonate, glucosamine/chondroitin sulphate prescription in the 12 month period
preceding index date; total number of GP consultations for knee or hip injury, non-osteoporotic fractures,
hand osteoarthritis, neck or back pain or spinal degenerative diseases, hypertension, duration of OA prior
to index date; number of analgesic prescription between the  rst consultation for knee/hip OA and beta-
blocker prescription; ≠β-blocker properties independent of each other; MSE: membrane stabilising effect.




The association between propranolol and knee or hip replacement: Kaplan-Meier survival estimates
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